Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.94 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.74 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | NCF1 | P14598 | 1/20 | 0.68 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11196296 | 0.97 | HRH3 (0.90) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| SCHEMBL4277270 | 0.97 | HRH3 (1.00) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| Hydrochloric Acid SCHEMBL7468055 | 0.95 | HRH3 (0.95) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| SCHEMBL6057527 | 0.92 | HRH3 (0.81) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| SCHEMBL7937990 | 0.90 | ALDH1A1 (0.95) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| SCHEMBL6057453 | 0.90 | HRH3 (0.77) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| SCHEMBL2250410 | 0.88 | HRH3 (0.74) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| Hydrochloric Acid SCHEMBL2334519 | 0.88 | HRH3 (0.74) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| SCHEMBL22711410 | 0.88 | HRH3 (0.74) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| SCHEMBL1276590 | 0.88 | ALDH1A1 (1.00) | HRH3HRH4ALDH1A1KDM4EMBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117820255-A | Application of catalyst and degradation method of ester substance | 上海科技大学 | 2024-04-05 | — | — | CN | disclosed |
| US-11517565-B2 | Bis-amines, compositions, and uses related to CXCR4 inhibition | EMORY UNIVERSITY (US) | 2022-12-06 | — | — | US | disclosed |
| US-20200316040-A1 | Bis-amines, Compositions, and Uses Related to CXCR4 Inhibition | UNIV EMORY (US) | 2020-10-08 | — | — | US | disclosed |
| US-10709697-B2 | Bis-amines, compositions, and uses related to CXCR4 inhibition | EMORY UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190008840-A1 | Bis-amines, Compositions, and Uses Related to CXCR4 Inhibition | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-10 | — | — | US | disclosed |
| US-4414220-A | HUPOGLYCEMIC, ANTIDIABETIC | PFIZER INC. (US) | 1983-11-08 | — | — | US | disclosed |
| US-4333932-A | DIHYDROISOINDOLES, HYPOGLYCEMIC, ANTIDIABETIC | PFIZER INC. (US) | 1982-06-08 | — | — | US | disclosed |
| EP-0010896-B1 | ORGANIC DIAMINE COMPOUNDS FOR USE AS ORAL HYPOGLYCEMIC AGENTS AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1981-12-30 | — | — | EP | disclosed |
| US-4220650-A | HYPOGLYCEMIC | PFIZER INC. (US) | 1980-09-02 | — | — | US | disclosed |
| EP-0010896-A1 | Organic diamine compounds for use as oral hypoglycemic agents and pharmaceutical compositions thereof | PFIZER INC. (US) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11517565-B2 | Bis-amines, compositions, and uses related to CXCR4 inhibition | CXCR4, CXCL12, CXCR2 | HRH3 243/4885HRH4 531/4885ALDH1A1 453/4885 |
| US-20200316040-A1 | Bis-amines, Compositions, and Uses Related to CXCR4 Inhibition | CXCR4, CXCL12, CXCR2 | HRH3 243/4885HRH4 531/4885ALDH1A1 453/4885 |
| US-10709697-B2 | Bis-amines, compositions, and uses related to CXCR4 inhibition | CXCR4, CXCL12, CXCR2 | HRH3 246/4885HRH4 514/4885ALDH1A1 447/4885 |
| US-20190008840-A1 | Bis-amines, Compositions, and Uses Related to CXCR4 Inhibition | CXCR4, CXCL12, CXCR2 | HRH3 246/4885HRH4 514/4885ALDH1A1 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.